1. Home
  2. AMS vs CODX Comparison

AMS vs CODX Comparison

Compare AMS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

N/A

Current Price

$2.09

Market Cap

13.8M

Sector

Health Care

ML Signal

N/A

Logo Co-Diagnostics Inc.

CODX

Co-Diagnostics Inc.

N/A

Current Price

$0.26

Market Cap

15.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMS
CODX
Founded
1980
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
15.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AMS
CODX
Price
$2.09
$0.26
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.25
AVG Volume (30 Days)
11.5K
1.7M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,423,000.00
$507,892.00
Revenue This Year
$3.81
N/A
Revenue Next Year
N/A
$18.89
P/E Ratio
N/A
N/A
Revenue Growth
17.84
N/A
52 Week Low
$2.01
$0.23
52 Week High
$3.52
$1.55

Technical Indicators

Market Signals
Indicator
AMS
CODX
Relative Strength Index (RSI) 45.92 38.62
Support Level $2.03 $0.24
Resistance Level $2.18 $0.41
Average True Range (ATR) 0.06 0.03
MACD 0.01 -0.01
Stochastic Oscillator 31.54 15.33

Price Performance

Historical Comparison
AMS
CODX

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.

About CODX Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Share on Social Networks: